Pfizer jab 97% effective against symptomatic COVID: study

Pfizer-Biontech found that prevention against asymptomatic disease also reached 94%

Last updated: March 11, 2021 | 16:37

Reuters

1 MIN READ

A vial of the Pfizer-BioNTech Covid-19 vaccine, in Haxby, northern England on December 22, 2020.

AFP

Also In This Package

Fighting COVID-19 by keeping things extremely cool

Cold, hard mission for a US warehouse: Help stop COVID-19

Vaccine: '90% effective, great day for public health'

'Great day for public health', as vaccine more than 90% effective, claims Pfizer

In Pictures: Dubai's free Covid-19 Pfizer vaccine drive

In Pictures: Dubai residents queue up to receive COVID-19 vaccination

In photos: Dubai kicks off Pfizer-BioNTech vaccine plan

In photos: Dubai kicks off Pfizer-BioNTech COVID-19 vaccine plan

Japan starts vaccine rollout with healthcare workers

Japan starts COVID-19 vaccine rollout with healthcare workers

In pictures: Pfizer COVID-19 vaccine arrives in Dubai

Berlin: Pfizer-Biontech's coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97 per cent, according to real world evidence published Thursday by pharma companies.

Using data from January 17 to March 6 from Israel's national vaccination campaign, Pfizer-Biontech found that prevention against asymptomatic disease also reached 94 per cent.

An earlier real world study had showed effectiveness at preventing symptomatic disease at 94 per cent and asymptomatic illness at 92 per cent.